Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese Male Subjects

Wyeth is now a wholly owned subsidiary of Pfizer24 enrolled

Overview

This study is being conducted to assess the safety and tolerability of ascending multiple oral doses of SCA-136 administered to healthy Japanese male subjects.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Schizophrenia

Interventions

SCA-136DRUG

Eligibility

Sex: MALEMin age: 20 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion criteria: * Healty Japanese men willing to use a medically acceptable form of contraception. Exclusion criteria: * Any significant disease * Positive urine drug screen * Increased liver function tests * Use of prescription drugs.

Locations (1)

Unnamed facility

Ikebukuro, Toshima-ku, Japan

Outcomes

Primary Outcomes

Adverse events, safety laboratory results, vital signs, and ECGs will be used to monitor subject safety.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.